Biohope presents the results of the BIOTRAIM study at the World Transplant Congress 2025: “Pretransplant Response to Immunosuppressants Measured with Immunobiogram Predicts First-Year Rejection in Kidney Transplant Recipients”

Biohope, a biotechnology R&D company specialized in precision medicine has participated in the World Transplant Congress (WTC 2025) in San Francisco held in August 2025. 

The BIOTRAIM study aimed to evaluate the ability of the Immunobiogram® performed pre-transplant to predict rejection in patients over one-year follow-up period, in addition to the risk estimated by traditional clinical factors (such as donor´s age and type, recipient´s age, immunological incompatibility between both, DSA and existence of a previous transplant). The results show that Immunobiogram® provides additional information beyond that offered by conventional clinical factors,  not only in patients at high risk of rejection, but also in those at low or medium risk. According to these data, the sensitivity profile of patients to immunosuppressants measured with Immunobiogram®, should be considered as a relevant criterion for selecting the immunosuppressive therapy in any renal transplant candidate, regardless of their clinical risk.

From the 1,550 abstracts submitted to the congress in the field of renal transplantation, this abstract  was included in a final selection of the 30 considered more relevant and presented at the closing plenary session ('Reflection, Revelations and the Road Ahead').  The WTC congress represents a strategic opportunity for Biohope to raise awareness of its technology and research results among the international transplant community. Biohope aims to contribute to the advancement of personalisation and optimisation of immunosuppressive therapies in transplantation, and is preparing to enter the US market.